Six Decades of Heritage,
One Constant Heart, Infinite Progress.
With over 25 years of dedication to Taiwan’s stem cell production and storage industry,
Supercell Biotechnology has quietly cultivated excellence in regenerative medicine.
From the founding of the Food Industry Research and Development Institute by President Hsieh Cheng-yuan (謝成源), to the establishment of Sino Cell Technologies (now Supercell Biotechnology Corporation) by his successor, President Hsieh Chung-pi (謝忠弼), and President Ho Mei-ching (何美慶), to the leadership of the RMT Global Holding Group and Supercell Biotechnology Corporation under Chairman Sean Ishihara (石原 智博) —this journey is more than a story of heritage. It represents the burgeoning future of regenerative medicine, a commitment that continues to enhance human well-being.
Better Quality of Life
Message from the Chairman
Medical advancement belongs to all of humanity. Especially in the wake of COVID-19, the world has come to realize our shared destiny—a future where human health is interconnected through coexistence and mutual prosperity. Medicine knows no borders.
For over 25 years, Supercell Biotechnology has been a pioneer in cell development, specializing in cell storage, screening, and clinical applications. Throughout our journey, an unwavering commitment to quality and professionalism has remained our most vital promise to our clients.
As global biotech R&D and clinical trials continue to expand, Supercell Biotechnology is poised to invest further resources. By integrating advanced technologies and state-of-the-art equipment with our global strategic partners, we are co-developing innovative solutions in preventive and regenerative medicine. Our goal is to harness the body’s most fundamental healing potential through the application of pluripotent stem cells and immune cells, ensuring a healthier and more vibrant future for all.
Our first 25 years were dedicated to the mastery of stem cell storage;
our next 25 years will be committed to the comprehensive realization of regenerative medicine.
Chairman, RMT Global Holding Group and Supercell Biotechnology Corporation
Sean Ishihara
Milestones of Supercell Biotechnology
2025
’2024′
’Annual
2022
RMT Global Holding Group acquired Sino Cell Technologies and officially rebranded the company as Supercell Biotechnology Corporation. Supercell Biotechnology has strategically pivoted toward advanced biotechnology and regenerative medicine to expand into the global healthcare market.
2021
Approved under the "Regulations Governing the Application of Specific Medical Techniques" for the Autologous Immune Cell (NK Cell) therapy program targeting Stage IV solid tumors.
2020
Established a technical collaboration with Changhua Christian Hospital for Autologous Immune Cell Therapy (NK cells).
2019
Exclusively licensed patented immune cell therapy technology developed by Dr. Hiroshi Terunuma, a renowned Japanese expert in immunotherapy and oncology.
2018
Hosted Dr. Joanne Kurtzberg, a world-renowned expert in cord blood stem cell applications, for a high-level meeting with the Ministry of Health and Welfare (MOHW) to advance cell therapy development in Taiwan.
2016
Became the sole founding member from Taiwan of the international Cord Blood Association (CBA).
2014
Exclusively secured the U.S. patent for "Serum-Free Culture Medium" (Patent No.: US 8762074 B2).
2013
Established a Peripheral Blood Stem Cell (PBSC) Bank, which passed the Ministry of Health and Welfare’s on-site inspection and was licensed under the "Regulations for Administration on Human Organ Bank."
2010
Initiated an industry-academic collaboration with Yuan Ze University to develop "Isolation and establishment of endothelial progenitor cells from cord blood ."
2009
Signed an agreement with National Yang-Ming University (now National Yang Ming Chiao Tung University), becoming the first cord blood company in Taiwan to officially license patented "Umbilical Cord Mesenchymal Stem Cell" culture technology.
2008
Partnered with Taipei Medical University to establish quality control standards for the storage of Mesenchymal Stem Cells (MSCs) from umbilical cord and amniotic tissue.
2007
Collaborated with medical teams from National Taiwan University Hospital and Chang Gung Memorial Hospital to complete Taiwan’s first successful case of using autologous cord blood to treat cerebral palsy.
2006
The self-developed “Umbilical Cord Blood Portable Incubactor" was honored with the National Innovation Award.
2004
The first institution in Taiwan to introduce the Taylor-Wharton LABS-80K, a large-scale liquid nitrogen vapor phase storage system.
2001
Established the Cell Storage And Application Center within the Bioresource Collection and Research Center (BCRC) at the Food Industry Research and Development Institute (FIRDI).